Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- SLN
- Price
- 2.57
- Stock movement up
- +0.38 (17.35%)
- Company name
- Silence Therapeutics PLC
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 121.34M
- Ent value
- 134.26M
- Price/Sales
- 7.47
- Price/Book
- 1.28
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 8.23%
- 1 year return
- -87.85%
- 3 year return
- -47.72%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
SLN does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 7.47 |
| Price to Book | 1.28 |
| EV to Sales | 8.26 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 47.21M |
| EPS (TTM) | -1.59 |
| FCF per share (TTM) | -1.19 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 16.25M |
| Gross profit (TTM) | 7.27M |
| Operating income (TTM) | -58.31M |
| Net income (TTM) | -58.86M |
| EPS (TTM) | -1.59 |
| EPS (1y forward) | -0.50 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 44.78% |
| Operating margin (TTM) | -358.97% |
| Profit margin (TTM) | -362.34% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 61.95M |
| Net receivables | 16.56M |
| Total current assets | 157.51M |
| Goodwill | 7.54M |
| Intangible assets | 258.00K |
| Property, plant and equipment | 0.00 |
| Total assets | 169.38M |
| Accounts payable | 14.27M |
| Short/Current long term debt | 139.00K |
| Total current liabilities | 16.91M |
| Total liabilities | 74.87M |
| Shareholder's equity | 94.52M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -43.83M |
| Capital expenditures (TTM) | 117.00K |
| Free cash flow (TTM) | -43.95M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -62.28% |
| Return on Assets | -34.75% |
| Return on Invested Capital | -62.19% |
| Cash Return on Invested Capital | -46.43% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.21 |
| Daily high | 2.59 |
| Daily low | 2.21 |
| Daily Volume | 376K |
| All-time high | 28.35 |
| 1y analyst estimate | 53.70 |
| Beta | 1.29 |
| EPS (TTM) | -1.59 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| SLN | S&P500 | |
| Current price drop from All-time high | -90.93% | -12.89% |
| Highest price drop | -92.31% | -56.47% |
| Date of highest drop | 9 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -41.87% | -11.07% |
| Avg time to new high | 35 days | 12 days |
| Max time to new high | 953 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
121.34M
Marketcap category
Small-cap
Description
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
Employees
109
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page